Floatz logo

Vinorelbine

Minimally Invasive Lung Adenocarcinoma

National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Minimally Invasive Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
NRG Oncology
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Panobinostat
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →